端点技术解决方案提供商Clario宣布完成对WCG的eCOA业务的收购-动脉网

Clario Announces Completion of Acquisition of WCG's eCOA Business

CISION 等信源发布 2025-05-06 22:00



可切换为仅中文







Clario strengthens its leadership in

Clario加强了其在

digital

数字的

endpoint data collection with the acquisition of WCG's eCOA business, enhancing support for neuroscience clinical trials.

通过收购WCG的eCOA业务，增强对神经科学临床试验的支持，进行端点数据收集。

Acquisition expands Clario's extensive capabilities in study design,

收购扩大了Clario在研究设计方面的广泛能力，

clinical outcomes

临床结果

assessments, centralized image analysis, and regulatory guidance for complex trials.

评估、集中式图像分析和复杂试验的监管指导。

Continues Clario's investments in innovation and growth to drive advancements in high-quality clinical trial data solutions.

继续Clario对创新和增长的投资，以推动高质量临床试验数据解决方案的进步。

PHILADELPHIA

费城

，

May 6, 2025

2025年5月6日

/PRNewswire/ --

Clario

克拉里奥

, a leading provider of digital endpoint data solutions to the clinical trial industry today announced completion of its acquisition of WCG's electronic clinical outcome assessment (eCOA) business. This strategic move enhances Clario's ability to provide best-in-class data collection and analysis solutions for neuroscience drug development, reinforcing its commitment to delivering high-quality, reliable data across all therapeutic areas..

，一家为临床试验行业提供数字终点数据解决方案的领先供应商，今天宣布已完成对WCG的电子临床结果评估（eCOA）业务的收购。这一战略性举措增强了Clario提供神经科学药物开发领域一流的数据收集与分析解决方案的能力，进一步巩固了其在所有治疗领域提供高质量、可靠数据的承诺。

'I am excited to bring WCG's eCOA team and technologies to Clario,' said

“我很兴奋能将WCG的eCOA团队和技术带到Clario，”

Chris Fikry

克里斯·菲克里

, M.D., chief executive officer, Clario. 'Along with our recent acquisition of neurology imaging analysis experts, NeuroRx, we are positioned to be the true leader in delivering endpoint data solutions to neuroscience clinical trials. Our clients now have access to the most reliable, high-quality data across multiple modalities and all major neuroscience endpoints.

Clario首席执行官M.D.表示：“随着我们最近收购了神经影像分析专家NeuroRx，我们有望成为为神经科学临床试验提供终点数据解决方案的真正领导者。我们的客户现在可以获得跨多种模式和所有主要神经科学终点的最可靠、高质量的数据。”

This will have wide-ranging benefits for our customers and to patients in this area of significant unmet medical need.'.

这将为我们的客户和这一具有重大未满足医疗需求领域的患者带来广泛的好处。

The addition of WCG's eCOA capabilities further amplifies Clario's leadership position in providing support for neuroscience drug development, which includes:

WCG的eCOA功能的加入进一步巩固了Clario在为神经科学药物开发提供支持方面的领导地位，其中包括：

Study design and protocol development

研究设计与方案开发

Site selection and training

站点选择与培训

Clinical outcomes assessments

临床结果评估

Centralized image analysis

集中式图像分析

Cardiac safety expertise

心脏安全专业技能

Quantitative movement analysis

定量运动分析

Regulatory guidance

监管指南

'This acquisition is a game-changer for clinical research in neuroscience,' said

“这次收购将改变神经科学临床研究的游戏规则，”

Terry Burke

特里·伯克

, executive vice president and general manager of Clario's eCOA business. 'WCG has made significant contributions to eCOA in neuroscience trials, and we have long respected their achievements in this space. We've planned a seamless integration with an aim on preserving what's already working well — trials will continue uninterrupted, and the platforms and study teams customers rely on will remain in place.

，Clario的eCOA业务执行副总裁兼总经理。“WCG在神经科学试验的eCOA领域做出了重要贡献，我们一直非常尊重他们在这一领域的成就。我们计划进行无缝整合，重点在于保留已经行之有效的部分——试验将继续不间断进行，客户所依赖的平台和研究团队也将保持不变。

By bringing WCG's eCOA professionals and scientific capabilities to Clario, we can deliver the high-quality data and scientific rigor needed to support new complex studies and to accelerate breakthrough therapies.' .

通过将WCG的eCOA专业人员和科学能力引入Clario，我们能够提供高质量的数据和科学严谨性，以支持新的复杂研究并加速突破性疗法的发展。

Astorg and Nordic Capital — two leading private equity firms with deep expertise in the healthcare sector — have co-owned Clario since 2019. Novo Holdings and Cinven also support the company as minority shareholders.

Astorg 和 Nordic Capital —— 两家在医疗保健领域拥有深厚专业知识的领先私募股权公司 —— 自 2019 年以来共同拥有 Clario。Novo Holdings 和 Cinven 也作为少数股东支持该公司。

Judith Charpentier

朱迪思·夏彭蒂尔

, co-head of Flagship & head of Healthcare at Astorg, and

，Astorg的旗舰基金联席主管兼医疗保健主管，以及

Daniel Berglund

丹尼尔·伯格伦德

, co-head of Healthcare at Nordic Capital Advisors, commented in a joint statement:

，北欧资本顾问公司医疗保健部门的联合主管，在联合声明中评论道：

'We are truly excited about Clario's strategic acquisition of WCG's eCOA business, which will further strengthen its position as a global leader in clinical trial endpoint solutions. We are proud to continue our collaboration with Clario's leadership team and support the company's continued growth and innovation journey.'.

“我们对Clario战略收购WCG的eCOA业务感到非常兴奋，这将进一步巩固其作为临床试验终点解决方案全球领导者的地位。我们很自豪能够继续与Clario的领导团队合作，支持公司的持续增长和创新之旅。”

For more information about Clario and its solutions, please visit clario.com.

有关Clario及其解决方案的更多信息，请访问clario.com。

About Clario

关于Clario

Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies. We offer comprehensive evidence-generation solutions that combine medical imaging, eCOA, precision motion, cardiac solutions and respiratory endpoints..

Clario是为临床试验行业提供终点数据解决方案的领先供应商，为生命科学公司生成高质量的临床证据。我们提供全面的证据生成解决方案，结合了医学影像、电子临床结果评估（eCOA）、精密运动、心脏解决方案和呼吸终点。

For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have been deployed over 26,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.

五十多年来，Clario 一直提供深厚的科学专业知识和广泛的终点技术，助力改变全球人们的生活。我们的终点数据解决方案已部署超过 26,000 次，支持了 100 多个国家的临床试验。自 2012 年以来，我们由科学、技术和运营专家组成的全球团队已参与支持了超过 60% 的 FDA 药物批准。

Clario's shareholders are Astorg, Nordic Capital, Novo Holdings, and Cinven..

Clario的股东是Astorg、Nordic Capital、Novo Holdings和Cinven。

For more information, go to

欲了解更多信息，请访问

Clario.com

or follow us on

或者关注我们

领英

。

Clario Media Contact:

克拉里奥媒体联系人：